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Abstract: Two graph theoretic concepts—clique and bipartite graphs—are explored to identify the
network biomarkers for cancer at the gene network level. The rationale is that a group of genes
work together by forming a cluster or a clique-like structures to initiate a cancer. After initiation,
the disease signal goes to the next group of genes related to the second stage of a cancer, which can be
represented as a bipartite graph. In other words, bipartite graphs represent the cross-talk among the
genes between two disease stages. To prove this hypothesis, gene expression values for three cancers—
breast invasive carcinoma (BRCA), colorectal adenocarcinoma (COAD) and glioblastoma multiforme
(GBM)—are used for analysis. First, a co-expression gene network is generated with highly correlated
gene pairs with a Pearson correlation coefficient ≥ 0.9. Second, clique structures of all sizes are isolated
from the co-expression network. Then combining these cliques, three different biomarker modules
are developed—maximal clique-like modules, 2-clique-1-bipartite modules, and 3-clique-2-bipartite
modules. The list of biomarker genes discovered from these network modules are validated as the
essential genes for causing a cancer in terms of network properties and survival analysis. This list
of biomarker genes will help biologists to design wet lab experiments for further elucidating the
complex mechanism of cancer.
Keywords: bipartite graph; clique; network biomarker; Pearson correlation coefficient (PCC); gene
co-expression network
1. Introduction
The present work is motivated by the prospective applications of protein-protein interaction (PPI)
networks to diseases and other dynamic processes. Ideker and Sharan [1] enumerated four different
applications of protein networks to diseases: i) identifying new disease genes, ii) studying the network
properties of disease genes, iii) classifying diseases based on protein network, and iv) identifying
disease-related subnetworks. Genome-wide PPI networks come with rich information about the
dynamic processes such as the behavior of genetic networks in response to DNA damage [2] and
exposure to arsenic [3], the prediction of protein function [4], genetic interaction [5], protein subcellular
localization [6–11], the process of aging [12], and protein network biomarkers [13–15].
One of the widely used methods for elucidating biomarkers for diseases is through protein-protein
interaction (PPI) or gene co-expression networks based on “guilt by association” concept. In a gene
co-expression network, nodes represent the genes and edges represent the connection between genes
due to significantly similar expression patterns over different samples. Several methods exist for
inferring edges in gene networks. Pearson correlation is one of the most common co-expression
measures employed in various studies [16,17]. Another common method, Mutual Information (MI) [18]
is an information theoretic measure for measuring nonlinear relationship between genes or other
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variables. A threshold is applied after constructing the co-expression network to retain the most
biologically significant correlations between genes.
The main purpose of analyzing gene co-expression networks is to identify the biologically
significant modules consist of groups of genes with dense interactions. Usually, highly connected groups
have a higher within-group homogeneity and can be considered as biologically significant modules
performing a common task, such as shared regulatory inputs or functional pathways. Clustering is
a popular method for finding relevant modules from gene co-expression networks. Weighted Gene
Correlation Network Analysis (WGCNA) is the most widely used package for module finding [19]
which applies hierarchical clustering to find modules. It applies a soft threshold during construction of
a gene co-expression network. Several researchers have identified key differentially expressed genes
associated with different cancers, such as breast, cervical, colon, esophageal, osteosarcoma and ovarian
cancers [20–26], using WGCNA.
Lui et al. [27] used differential entropy technique to identify key genes in diabetes using rat’s
time-series gene expression data from case and control samples. Guan et al. [28], developed a prediction
model using Bayes discriminant method to predict the prognosis of hepatocellular carcinoma based on
gene co-expression network.
Graph theoretic methods are also applied for analysis of gene co-expression networks. Shi et.al. [29],
proposed an algorithm named Iterative clique enumeration technique (ICE) to discover relatively
independent maximal cliques for breast cancer on GEO dataset and found some highly correlated
modules that may indicate the tumor grades. Similarly, Perkins et al. used spectral graph theory on
Homo sapiens and Saccharomyces cerevisiae microarray data for clustering at various thresholds [30].
Zhang et al. [31], discovered the top five hub genes for bladder cancer using the centrality analysis method.
None of the previous studies used clique and bipartite combination to identify the biologically
significant modules. The main goal of this paper is to explore the existence of clique-bipartite-like
network modules in actual gene network for cancer. Mondal et al. [32] showed that clique-like
structures and bipartite graphs could be the building blocks for disease progression, Figure 2 in [32].
The rationale is that a group of proteins or genes work together by forming a network (a clique-like
structure) to accomplish a specific function, which could be related to a disease stage [32] and bipartite
structure represents the cross-talk among genes between two disease stages.
In this study, gene co-expression network was constructed using highly correlated gene pairs
with PCC ≥ 0.9. Three network modules—maximal clique-like graph, 2-clique-1-bipartite graph,
and 3-clique-2-bipartite graph—are identified. Finally, the effectiveness of the key genes discovered
from these network modules was validated using pathway and survival analyses.
2. Results
Three different types of cancers—breast invasive carcinoma (BRCA), colorectal adenocarcinoma
(COAD), and glioblastoma multiforme (GBM)—are considered in the present study to identify network
biomarkers. Gene correlation networks based on gene expression profiles of BRCA (20,155 genes for
1093 samples), COAD (19,828 genes for 379 samples), and GBM (19,660 genes for 153 samples) are
developed with highly correlated gene pairs (PCC≥ 0.9). From these networks, three types of gene network
modules, considered as network biomarkers, are isolated: i) Single clique-like module based on maximal
cliques named as “maximal clique-like” module, ii) clique-bipartite-like modules with two cliques and
one bipartite graph named as “2-clique-1-bipartite” modules, which are discovered based on two cliques
connected with maximum number of inter-clique connections, and iii) clique-bipartite-like modules with
three cliques (A, B, C) and two bipartite graphs (A-B and B-C) named as “3-clique-2-bipartite” modules,
which are discovered based on two bipartite graphs having relatively more edges compare to others.
This section is organized in following subsections: Section 2.1—results with the topology
of gene co-expression networks; Section 2.2—results with cliques and maximal clique-like
modules; Section 2.3—results with 2-clique-1-bipartite modules; and Section 2.4—results with
3-clique-2-bipartite modules.
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2.1. Topology of Gene Co-Expression Networks
Table 1 shows the topology of gene co-expression networks for three cancers—BRCA, COAD,
and GBM—generated using gene pairs with PCC ≥ 0.9. The network for COAD is the largest and
densest composed of 607 genes and 3651 interactions with an average degree of 12. The network for
BRCA is the smallest composed of 380 genes and 1034 interactions, which is a sparse network with an
average degree of 5.4. The network for GBM is the sparsest with an average degree of 4.9.
Table 1. Topology of gene co-expression network with PCC > 0.9.
Cancer Name # Of Genes # Of Edges Max Degree Min Degree Avg Degree
BRCA 380 1034 39 1 5.4
COAD 607 3651 75 1 12.0
GBM 506 1243 49 1 4.9
2.2. Cliques and Maximal Clique-Like Modules
NetworkX [33], a python package, was used to discover cliques of all possible sizes. The total
number of cliques are 209, 1535, and 322 for BRCA, COAD, and GBM, respectively. The size of cliques
and the corresponding number of cliques (frequency) for each cancer are presented in Supplementary
Table S1. It is clear from this table that small-sized cliques (3-node, 4-node, etc.) appear more than the
cliques of larger size, as expected. The gene co-expression networks for BRCA, COAD, and GBM have
3, 10, and 6 maximal cliques with 17, 19, and 11 genes, respectively, Supplementary Table S1.
For a particular cancer, most of the genes in maximal cliques are in common, Supplementary
Table S2. Thus, it is better to combine the maximal cliques for a cancer to have a single maximal
clique-like module for further analysis. The maximal clique-like modules for three cancers—BRCA,
COAD, and GBM—are shown in Supplementary Figure S1. Finally, the maximal clique-like modules
have 19, 30, and 14 genes for BRCA, COAD, and GBM, respectively, as shown in Table 2. Based on these
modules, COAD and GBM cancers share six genes—CD4, HCK, ITGB2, LAIR1, LAPTM5, and SPI1.
However, BRCA does not share any genes with the other two cancers. It can be concluded from the
maximal clique-like modules that BRCA cancer has a unique behavior which is different from COAD
and GBM, whereas COAD and GBM might have some common characteristics.
Table 2. List of genes in maximal clique-like modules for three Cancers—BRCA, COAD, and GBM.
Cancer List of Genes in Maximal Clique-Like Modules
BRCA CD2, CD247, CD3D, CD3E, CD5, CD96, CXCR3, IL2RG, LCK, LY9, PTPN7, SH2D1A, SIRPG, SIT1,SLA2, SLAMF1, SLAMF6, TBX21, UBASH3A
COAD
C1QB, C1QC, C3AR1, CD300A, CD4, CD53, CD86, CLEC7A, CSF1R, CYBB, CYTH4, DOK2,
FCER1G, FPR3, HAVCR2, HCK, ITGB2, LAIR1, LAPTM5, LILRB1, LILRB4, LRRC25, MS4A4A,
PDCD1LG2, SIGLEC7, SIGLEC9, SLAMF8, SPI1, TFEC, TYROBP
GBM ALOX5, CD4, FERMT3, HCK, ITGB2, LAIR1, LAPTM5, NCKAP1L, PTPN6, SASH3, SPI1, STXBP2,VAV1, WAS
2.3. 2-Clique-1-Bipartite Modules
Figure 1 shows clique-bipartite-like modules composed of two cliques and one bipartite graph for
BRCA, COAD, and GBM. The nodes in two cliques are represented by yellow (Clique-1) and gray (Clique-2)
colors. Intra-clique connections are blue and inter-clique connections, forming a bipartite graph, are red.
In identifying clique-to-clique connections, it is made sure that the two cliques do not have any gene in
common. Finding the interconnected cliques is a combinatorial problem. Usually, cliques or cluster of
genes representing different stages of a disease are more likely to have cross-talks or interconnections
between two cliques. Bipartite graphs between genes of two stages represent the cross-talks. This study
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focuses on identifying cliques with maximal connections (cross-talks) only. There are 59, 145, and 44 edges
that are connecting two cliques in Figure 1a–c, which are the highest in three respective cancers.Data 2019, 4, 81 4 of 12 
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Figure 1. Clique-bipartite-like modules with maximal interconnections between two cliques. (a) BRCA;
(b) COAD; and (c) GBM. Nodes in Clique-1 are yellow and nodes in Clique-2 are grey colored.
Intra-clique connections are blue and inter-clique connections (a bipartite graph) are red.
Table 3 shows the list of genes discovered from these clique-bipartite-like modules. Based on these
modul , COAD and GBM cancers sh re many genes in common. The common genes—in clique1 for
both anc rs are HCK, ITGB2, LAIR1, and LRRC25, and for clique2 re CD4, CD53, LILRB1 NCKAP1L,
and SPI1. LAPTM5 is the only common gene between clique1 of GBM and clique2 of COAD. On the
other hand, BRCA does not share any gene in common. It can be concluded from 2-clique-1-bipartite
modules that BRCA cancer has unique behavior, which is different from COAD and GBM cancers,
whereas COAD and GBM might have some common characteristics.
Table 3. List of genes in 2-clique-1-bipartite modules.
BRCA COAD GBM
Clique1
CCL5, D2, 47,
CD3D, CD3E, CXCR3,
GZMA, IL2RG, SIRPG,
SLA2, TBX21
C1QB, C1QC, C3AR1, CD163, CLEC7A,
CMKLR1, CSF1R, FPR3, HCK, ITGB2,
LAIR1, LILRB2, LRRC25, SIGLEC7,
SLAMF8, TLR8
CD68, FERMT3, HCK,
ITGB2, LAIR1, LAPTM5,
LRRC25, SIGLEC9
Clique2
BTLA, ITK, LY9,
PYHIN1, SH2D1A,
SLAMF1, SLAMF6,
TRAT1, ZNF831
CD4, CD53, CD86, CYBB, CYTH4, DOCK2,
DOK2, LAPTM5, L P2, LILRB1,
NCKAP1L, SLA, SPI1
CD4, CD53, LILRB4,
NCKAP1L, PTPN6,
SASH3, SPI1, VAV1
2.4. 3-Clique-2-Bipartite Modules
The top three modules of 3-clique-2-bipartite from each cancer are considered for further analysis.
Table 4 summarizes these modules in terms of clique size and the number of inter-clique connections.
For example, BRCA-Module1 consists of three cliques of 13, seven, and four genes connected by two
bipartite graphs of 56 and 13 connections.
Table 4. Summary statistics of 3-clique-2-bipartite modules.
Clique-A Clique-B Clique-C Connections A-B Connections B-C
BRCA-Module1 13 7 4 56 13
BRCA-Module2 11 7 4 35 10
BRCA-Module3 8 6 6 8 18
COAD-Module1 16 14 7 85 53
COAD-Module2 16 14 6 111 51
COAD-Module3 16 12 7 69 40
GBM-Module1 9 9 5 30 19
GBM-Module2 9 7 6 22 23
GBM-Module3 9 7 4 36 14
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Figure 2 shows the top three 3-clique-2Clique-2-bipartite modules for BRCA. Modules for COAD
and GBM are shown in Figure S2. The nodes in three cliques are represented by yellow (clique-A),
grey (clique-B) and orange (clique-C) colors. Intra-clique edges are colored blue and inter-clique edges
are colored red.
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Figure 2. Top three 3-clique-2-bipartite modules for BRCA. Yellow nodes: Clique-A, gray nodes:
Clique-B, Orange nodes: Clique-C. Blue: Intra-clique edges, Red: Inter-clique edges. (a) Cliques A, B,
and C have 13, 7, and 4 nodes respectively. There are 56 connecting edges between cliques A and B
and 13 connecting edges between cliques B an .; ( ) liques A, B, and C have 11, 7, and 4 nodes
respectiv ly. There a 35 connecting edges betwe n and B and 10 connecting dges b tween
cliques B and C.; (c) Cliques A, B, and C have 8, 6, odes respectively. There are 8 con ecting
edges between cliques A and B and 18 connecting edges bet een cliques B and C.
The complete lists of genes that are present in each of the top three 3-clique-2-bipartite modules
for BRCA, COAD, and GBM are presented in Supplementary Table S3. Observation of these list reveals
that there are many genes in common in three modules of a particular cancer. Table 5 shows the
combined list—44, 48, and 32 genes for BRCA, COAD, and GBM respectively. Three cancers share four
genes—CD53, DOCK2, IKZF1, and NCKAP1L. Other than these four genes, BRCA and COAD share
three more genes—ITK, PTPRC, and TBC1D10C; COAD and GBM share 10 more genes—ARHGAP30,
CD4, CD86, CSF1R, HCK, ITGB2, LAIR1, LAPTM5, SASH3, and SPI; and BRCA and GBM do not share
any more genes. Thus, BRCA and COAD sh re a total of seven genes; COAD a d GBM share a total of
14 genes; and BRCA and GBM share only four ge es. Again, based o 3-clique-bipapartite modules,
COAD and GBM shares many genes, which means that they might have some common cause for
cancer development. These lists of common genes might provide better insight from lab experiments.
Table 5. Combined list of genes from top three 3-clique-2 bipartite modules.
List of Genes
BRCA-Modules
ACAP1, CCL5, CD2, CD247, CD3D, CD3E, CD3G, CD5, CD53 CD96, XCR3, CXCR6,
DOCK2, EVI2B, FYB, GZMA, GZMM, IKZF1, IL2RG, ITK, LCP2, LY9, NCKAP1L, PLEK,
PRF1, PRKCB, PTPRC, PTPRCAP, PYHIN1, S1PR4, SH2D1A, SIRPG, SIT1, SLA2, SLAMF1,
SLAMF6, SPN, TBC1D10C, TBX21, THEMIS, TRAT1, UBASH3A, ZAP70, ZNF831
COAD-Modules
APBB1IP, ARHGAP30, ARHGAP9, BTK, C3AR1, CD163, CD4, CD53, CD84, CD86,
L 7 , , , , 0, 2, FPR3, HAVCR2, HCK, HCLS1, IKZF1,
IL10RA, ITGAL, ITGB2, ITK, KLHL6, LAIR1, LAPTM5, LILRB1, LILRB4, LRRC25,
MAP4K1, MNDA, MYO1G, NCKAP1L, PIK3R5, PTPRC, RASAL3, SASH3, SIGLEC7,
SIGLEC9, SIRPB2, SLA, SLAMF8, SPI1, TBC1D10C, TRAF3IP3, WAS
GBM-Modules
ARHGAP30, ARL11, C1QA, C1QB, C1Q , CD33, CD4, CD53, CD68, CD86, CSF1R,
DOCK2, DOCK8, FCER1G, FCGR3A, FERMT3, HCK, IKZF1, ITGB2, LAIR1, LAPTM5,
MYO1F, NCF4, NCKAP1L, PLCG2, SASH3, SPI1, STXBP2, SYK, TYROBP, VAMP8, VAV1
3. Discussion
This section discusses the validation of key genes related to three cancers—BRCA, COAD,
and GBM—discovered from three network modules—maximal clique-like modules, 2-clique-1-bipartite
modules, and 3-clique-2-bipartite modules. First, since the key genes are discovered via network
modules, this paper used a network-based app, CytoHubba [34] for validation. The app, CytoHubba,
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is capable of ranking genes in a network using 12 different graph-theoretic algorithms. The reason
for using CytoHubba is that it produces successful results in predicting essential proteins from the
yeast protein-protein interaction network [34]. Similarly, in a cancer gene co-expression network,
the genes that cause cancer can be thought of as the essential genes for causing that cancer and most
likely will have the similar network properties as essential proteins in PPI network. Second, a survival
analysis is conducted to show the effectiveness of the key genes discovered using network modules.
Finally, pathway and GO term enrichment analyses are conducted for the key genes.
3.1. Validation Using CytoHubba
Figure 3 shows the validation process using two validation metrics—Top 20 genes and Top
50 genes—developed using CytoHubba. The original or base gene network (network created with PCC
≥ 0.9) are analyzed using 12 scoring methods—betweenness, bottleneck, closeness, clustering coefficient
(CC), degree, density of maximum neighborhood component (DMNC), eccentricity (EcC), edge
percolated component (EPC), maximal clique centrality (MCC), maximum neighborhood component
(MNC), radiality, and stress—of CytoHubba to create the list of genes as the benchmark for validation.
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etric-1 (Top-20 enes): First, Top-20 genes are taken from each of the 12 scoring ethods.
Then, the genes that appear in t o or ore scoring ethods are considered as the bench ark for
validation. The bench arks for BRCA, COAD, and GB cancers consist of 41, 53, and 42 genes,
respectively, see Supple entary Table S4.
Metric-2 (Top-50 Genes): Similarly, Top-50 genes are taken from each of the 12 scoring methods.
Then, the genes that appear in two or more scoring methods are considered as the benchmark for
validation. The benchmarks for BRCA, COAD, and GBM cancers consist of 92, 130, and 99 genes
respectively, see Supplementary Table S4.
Table 6 shows the number of key genes obtained by combining the unique genes from three
modules and the number of these key genes validated by metric-1 and etric-2. For example, 47 key
genes were discovered from three network modules of BRCA. These 47 key genes were then compared
with the benchmark genes in metric-1 and metric-2. Out of 47 key genes, 26 and 45 genes were
found to be common in metric-1 and metric-2, respectively. This validation supports that the list of
genes discovered using three modules—maximal clique-like modules, 2-clique-1-bipartite modules,
and 3-clique-2-bipartite modules—are essential genes for causing a cancer. This also supports the
proposed hypotheses that there exist clique-like and clique-bipartite-like structures, which can be
considered as network biomarkers for cancers.
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Table 6. Summary of validation.
Dataset. Key Genes
Keys Genes Common with
Metric-1 Metric-2
BRCA 47 26 45
COAD 61 23 53
GBM 38 25 36
3.2. Survival Analysis
Cox proportional hazard regression [35], a semi-parametric method was used for calculating the
Cox coefficients of the key genes (Supplemental Table S5). It can adjust survival rate estimation to
quantify the effect to predictor variables, which are key genes in the present study. The clinical data
of cancer patients (obtained from TCGA) were divided into two equal groups such that each group
had the same ratio of dead and alive. One of the groups were used as training set for calculation
of Cox coefficients of the key genes. Then, the prognostic risk of each patient in the test set was
calculated based on the expression values of key genes using the gene expression grade index (GGI) [36].
The following equation calculates the risk:
GGIRiskScore =
∑
xi −
∑
yi
where, xi and yi are the expression level of genes with positive and negative cox coefficient.
According to GGI risk score, patients in the test were divided into two groups, as high and low
risk groups. The patients with a top 50% GGI risk score are in the high-risk group and others are in the
low-risk group. Then a log-rank test was performed to see if there are significant difference in the real
survival risks between the two groups.
The survival analysis of key genes of three cancers is shown in Figure 4. It is clear from this figure
that the key genes of BRCA, COAD, and GBM are capable of distinguishing between cancer patients in
terms of survival in the respective cancers. The log rank p-values between high-risk and low-risk groups
were 0.0411, 0.0100, and 0.0171. Log-rank p-values below 0.05 means there is a significant difference
between the two groups in consideration. The hazard ratios between high-risk groups and low-risk
groups are 1.6478, 2.1627, and 1.6569 for cancer patients of BRCA, COAD, and GBM. This means,
for example, high-risk groups of COAD patients are 2.1627 more likely to die than low-risk patients.
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respective key genes as prognostic factors. The Kaplan–Meyer curve in blue is for the low-risk group
and in orange for the high-risk group. The shaded blue and orange regions around their respective
lines indicate the confidence interval. The y-axis is the probability of survival and the x-axis is the
duration in days.
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3.3. Pathway and Gene Ontology Enrichment of Key Genes
The pathway and Gene Ontology (GO) enrichment analyses are also performed for validation
of key genes (List of key genes can be found in Supplementary Table S5). Pathway analysis was
performed in ReactomeFIViz [37], a Cytoscape app. The false discovery rate (FDR) was calculated
based on P-values using Benjamini–Hochberg method. The top ten pathways enriched in three
cancers were compared. The pathways enriched in at least two cancers is listed in Supplementary
Table S6. TCR signaling in -ve CD4+ T cells is enriched in all three cancers. There are five other
pathways- Neutrophil degranulation, Osteoclast differentiation, Staphylococcus aureus infection,
Natural killer cell mediated cytotoxicity and Fc gamma R-mediated phagocytosis are enriched in
both COAD and GBM. This may be due to genes in common between COAD and GBM in maximal
clique-like modules and 2-clique-1 bipartite modules. BRCA showed unique behavior in both modules.
In 3-clique-2-bipartite module, BRCA had three genes in common with other two cancers and three
more in common with COAD. The pathway T cell receptor signaling pathway is the only pathway
enriched in both BRCA and GBM. In all three modules, COAD and GBM shared the same number
genes. This is further observed in the enriched pathways they share in common.
A Cytoscape app, BiNGO [38] was used for GO enrichment analysis in three categories- biological
process (BP), cellular component (CC), and molecular function (MF). BiNGO uses the Benjamini and
Hochberg (false discovery rate) statistical method for multiple testing correction. The top ten enriched
GO terms in three cancers were compared. GO terms common in at least two cancers are listed in
Supplementary Table S7.
The biological processes enriched in all three cancers are Immune system process, regulation of
immune system process, positive regulation of immune system, and T cell activation. Three more biological
processes are enriched in both BRCA and GBM, and two more are in COAD and GBM. Most of the common
enriched BPs are related to immune system. It is an accepted fact that immune cells have the ability to
influence cancer [39]. This is another validation of the key genes discovered in the present study.
There are five cellular components enriched in all three cancers—plasma membrane, plasma
membrane part, integral to plasma membrane, intrinsic to plasma membrane, and receptor complex.
The dysregulation of the structural integrity of plasma membrane or its domain is known to promote
oncogenic signaling [40]. Three other pathways—T cell receptor complex, membrane, and cell
surface—are enriched in at least two of three cancers.
The three molecular functions enriched in all three cancers are molecular transducer activity, signal
transducer activity, and protein binding. Two other molecular functions—GTPase regulatory activity
and nucleoside-triphosphatase regulator activity—are enriched in COAD and GBM while receptor
activity and non-membrane spanning protein tyrosine kinase are enriched in BRCA and COAD.
3.4. Future Direction
This study discovers key genes related to cancers from gene co-expression networks. There are
three epigenetic factors that drive the cancer via gene expression of cancer genes, which are: i) DNA
methylation, ii) histone modification, and iii) miRNA dysregulation. Future study will be conducted to
determine how these three epigenetic factors are related to the genes discovered in this study. A study
will be conducted for further analysis of the clique-like disease progression to identify the core clique,
which could be a clique of three or more genes, for initiating a cancer utilizing the information from
three epigenetic factors. Finally, we will explore how the core clique expands to a maximal clique-like
structure in the final stage of a cancer.
4. Materials and Methods
4.1. Dataset Preparation
Gene expression data for BRCA, COAD, and GBM are obtained from LinkedOmics [41].
The datasets consist of gene expression values of 20155 genes for 1093 samples, 19,828 genes for
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379 samples, and 19,660 genes for 153 samples, respectively, for BRCA, COAD, and GBM as mentioned
in Table 7. In these datasets, all samples are cancer patients.
Table 7. Summary of gene expression data for BRCA, COAD, and GBM.
Cancer No of Genes No of Samples Reduced no of Genes
Breast invasive carcinoma (BRCA) 20,155 1093 16,011
Colorectal adenocarcinoma (COAD) 19,828 379 15,769
Glioblastoma multiforme (GBM) 19,660 153 16,186
The missing values were imputed using the fancyimpute package in Python employing the
k-nearest neighbors algorithm. The number of genes in the reduced datasets are 16,011, 15,769,
and 16,186, respectively, for BRCA, COAD, and GBM. For the present study, highly correlated positive
gene pairs, PCC ≥ 0.9 in each cancer are considered for creating the base networks for further analysis.
4.2. Method to Identify Clique and Clique-Bipartite-Like Modules
To discover the cluster of genes or cliques and how they are connected to each other by
forming bipartite graphs, Python package NetworkX [33] is used. First, list of cliques with
different sizes are discovered. Then, using the list of cliques and the original network (network
created with PCC ≥ 0.9), three types of gene network modules, considered as network biomarkers,
are discovered—i) maximal clique-like modules, ii) 2-clique-1Clique-1-bipartite modules, and iii)
3-clique-2Clique-2-bipartite modules.
Maximal clique-like module: The discovered cliques are organized in a list based on their size
and frequency of occurrence. From the sorted list, the size and number of maximal (largest) cliques in
each cancer are found and then combined together to get the maximal clique-like module. This process
generates a single maximal clique-like module for each cancer.
2-Clique-1-bipartite module: These are clique-bipartite-like modules with two cliques and one
bipartite graph, which are discovered based on two cliques connected with maximum number of
inter-clique connections.
3-Clique-2-bipartite module: With the list of cliques and the original network (network created
with PCC ≥ 0.9), a list of three connected cliques A, B, and C is generated in a way such that clique
A is connected to clique B and clique B is connected to clique C, but cliques A, B, and C do not have
any common genes. This process takes longer than usual because of the high number of cliques and
the problem is combinatorial in nature. Every combination of three cliques is being checked to see
whether it fulfills the condition. These modules are identified by first sorting the list by number of
edges connecting cliques A and B and then sorting by number of edges connecting cliques B and C.
It is observed that if one of the edge-count (between cliques A and B) has the highest value then the
other edge-count (between cliques B and C) has very low value. Finally, from the sorted list, structures
having both the edge-counts higher than others are selected as the possible network modules for a
cancer. The top three structures from each cancer are considered for further analysis.
5. Conclusions
This paper used two graph theoretic concepts—clique and bipartite graphs—to identify the network
biomarkers for cancer from gene co-expression networks developed with highly correlated gene pairs.
The gene expression profiles of three cancers—BRCA, COAD, and GBM—are considered for experiment.
Results show that three types of network modules—maximal clique-like, 2-clique-1-bipartite,
and 3-clique-2-bipartite graphs—derived using the simple graph theoretic concepts clique and bipartite
graph are capable of representing cancer dynamics at the gene network level. The combined list of
genes from three network modules for a particular cancer are validated with the benchmark developed
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from a network-based tools CytoHubba. The effectiveness of the key genes is also validated by survival
and pathway analyses.
The discovered gene network modules provide a short list of genes related to cancer that can be
used by the biologist to design wet lab experiment for further elucidation of the complex mechanism
of cancer.
Supplementary Materials: The following are available online at http://www.mdpi.com/2306-5729/4/2/81/s1;
Figure S1. Maximal clique-like modules; Figure S2. Top three 3-clique-2-bipartite modules for COAD and GBM;
Table S1. Frequency of cliques according to sizes; Table S2. List of genes in maximal cliques; Table S3. List of
genes for top three 3-clique-2-bipartite modules; Table S4. List of benchmark genes in top-20 and top-50 metrics;
Table S5. List of genes combining three network modules; Table S6. Enriched pathways with key genes; Table S7.
GO term enrichment analysis.
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